Section Arrow
Quote
TPST.NASDAQ
- Tempest Therapeutics Inc
(Financial Status)
Quotes are at least 15-min delayed:2026/11/04 07:34 EST
Pre Market
Last
 0.4756
+0.007 (+1.49%)
Bid
0.4706
Ask
0.477
High 0.477 
Low 0.4612 
Volume 3.10K 
Regular Hours (Closed)
Last
 0.4686
-0.0034 (-0.72%)
Day High 
0.4998 
Prev. Close
0.472 
1-M High
0.825 
Volume 
140.98K 
Bid
0.4706
Ask
0.477
Day Low
0.4638 
Open
0.4965 
1-M Low
0.4701 
Market Cap 
9.44M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 0.52 
20-SMA 0.61 
50-SMA 0.81 
52-W High 10.3294 
52-W Low 0.4701 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.68/-0.90
Enterprise Value
16.39M
Balance Sheet
Book Value Per Share
-0.05
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
GERNGeron Corp0.93+0.0009+0.10%-- 
Pre Market 0.9829 +0.0529 +5.69%
CRISCuris Inc.0.7139+0.0529+8.00%0.18PE
Pre Market 1.77 +1.0561 +147.93%
INOInovio Pharmaceuticals1.66-0.23-12.17%-- 
Pre Market 1.6885 +0.0285 +1.72%
CNSYCerenome, Inc.1.3-0.41-23.98%0.58PE
Pre Market 1.2632 -0.0368 -2.83%
KTTAPasithea Therapeutics Corp0.53+0.162+44.02%-- 
Pre Market 0.492 -0.038 -7.17%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.